GATA6 Loss Unlocks a Hidden Switch Driving Colorectal Cancer Liver Metastasis
Key Insights
Loss of the transcription factor GATA6 (search) reprograms colorectal cancer (search) cells into a flexible, fetal-like state that promotes liver metastasis (search), according to a new study in Cell Stem Cell.
Researchers found that GATA6 (search) loss triggers lineage plasticity, shifting cells from LGR5 (search)-positive to LGR5-negative states with enhanced metastatic potential, while having little effect on primary tumor growth.
The findings suggest epigenetic changes, rather than specific genetic mutations, may be the key drivers of colorectal cancer (search) spread to the liver.
For many patients with colorectal cancer (search), the greatest threat is not the original tumor but its ability to spread to the liver. Once metastasis occurs, treatment becomes far more difficult and survival rates drop sharply. Now, a study from researchers at Weill Cornell Medicine and the Massachusetts Institute of Technology has identified a molecular switch that may explain how some colorectal cancer cells gain this deadly capability.
Published June 22 in Cell Stem Cell, the study reveals that loss of a gene-regulating protein called GATA6 (search) can push colorectal cancer (search) cells into a highly adaptable state that dramatically increases the likelihood of liver metastasis (search). The findings challenge the long-held assumption that specific genetic mutations drive metastasis, pointing instead toward epigenetic reprogramming as a central mechanism.
GATA6 (search): The Molecular Identity Keeper
Under normal conditions, GATA6 (search) functions as a transcription factor that maintains cellular identity in the intestinal lining. It acts as a molecular gatekeeper, controlling which genes are active and which remain silent, thereby keeping intestinal cells on their proper developmental path.
The research team discovered that this control system frequently breaks down in metastatic colorectal cancer (search). In both mouse models and patient samples, GATA6 (search) levels were substantially lower in liver metastases than in primary tumors. Low GATA6 expression was also linked to poorer clinical outcomes, suggesting that losing this protein removes an important safeguard against aggressive cancer behavior.
"We discovered that GATA6 (search) loss acts as a critical switch that can change cancer cells in the primary tumor from non-metastatic to pro-metastatic," said Dr. Norihiro Goto, assistant professor of medicine in the Division of Gastroenterology & Hepatology at Weill Cornell and co-leader of the study. "Our findings suggest that epigenetic changes may be more important for promoting liver metastasis (search)."
Unlike genetic mutations, which alter the DNA sequence itself, epigenetic changes affect how genes are used. They can dramatically reshape cellular behavior without changing the underlying genetic code, offering a different explanation for why no single driver mutation for liver metastasis (search) has been identified despite extensive research.
Recreating Metastasis in Real Time
A major obstacle in metastasis research is that scientists typically study tumors only after they have already spread, missing the early biological events that enabled the process. "When researchers analyze patient samples from liver metastases, we fail to capture the important signals occurring in the early stages of the metastatic process," Dr. Norihiro Goto explained.
To overcome this limitation, the team developed an innovative experimental system. They grew organoids—miniature three-dimensional clusters of cancer cells—from liver metastases and transplanted them into the colons of mice, where they formed new tumors that later spread to the liver. By repeatedly cycling through this process, the scientists observed how cancer cells gradually became more efficient at metastasizing.
Lineage Plasticity and the Fetal-Like State
The experiments revealed that losing GATA6 (search) triggers a phenomenon known as lineage plasticity, which allows cells to abandon their existing identity and adopt new characteristics. Rather than remaining specialized intestinal cells, the cancer cells activated genetic programs more commonly associated with fetal development. These fetal-like cells were far more flexible and appeared better equipped to survive the challenges of metastasis, including detaching from surrounding tissue, entering circulation, surviving immune defenses, and adapting to an entirely new environment.
The researchers identified a clear molecular signature associated with this transformation. As GATA6 (search) levels dropped, cancer cells shifted from an LGR5 (search)-positive state to an LGR5-negative state. Previous studies have shown that LGR5-negative cells possess an enhanced ability to initiate liver metastases. When researchers silenced GATA6, more cells adopted the LGR5-negative state and gained fetal-like characteristics linked to metastasis. Conversely, restoring GATA6 activity, or activating related molecular pathways, reduced the cells' ability to spread.
Metastasis Independent of Tumor Growth
One of the study's most striking findings was that removing GATA6 (search) dramatically increased liver metastasis (search) without significantly affecting primary tumor growth.
"When we genetically delete GATA6 (search), the frequency and burden of liver metastases in mouse models significantly increase, while having little effect on primary tumor growth," said Dr. Norihiro Goto, who is also a member of the Jill Roberts Institute for Research in Inflammatory Bowel Disease and the Sandra and Edward Meyer Cancer Center at Weill Cornell.
This decoupling of metastasis from tumor size suggests that the spread of cancer is driven by specific cell-state transitions rather than by growth rate alone—a finding with important implications for how clinicians assess disease progression.
Clinical Implications and Future Directions
The results suggest that GATA6 (search) could serve as a biomarker for metastatic risk. Tumors with low GATA6 levels may be more likely to contain cells capable of transitioning into a metastasis-promoting state, potentially helping doctors identify patients who need closer monitoring or more intensive treatment.
The findings also point toward a therapeutic strategy focused on preserving cell identity or preventing cancer cells from entering highly adaptable states. However, developing such treatments presents challenges because many of the same biological programs are also involved in normal tissue repair. Similar cellular reprogramming mechanisms are used by healthy tissues during wound healing and recovery from injury, meaning cancer may be exploiting a normal biological process for a dangerous new purpose.
Future research will seek to identify vulnerabilities unique to GATA6 (search)-deficient cancer cells that could be targeted with new drugs. The team also plans to investigate how the tumor microenvironment, including immune cells and signals from the liver, influences these cellular transitions in preclinical models.
"In addition to treating primary tumors, we need to find strategies to target the mechanism of liver metastasis (search)," Dr. Norihiro Goto said. "Our study is a step toward developing therapies that block the spread of cancer at the earliest stages."